NYSEAMERICAN:ELMDElectromed Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Electromed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Electromed.

Electromed is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Electromed.

Electromed, Inc. (NYSEAMERICAN:ELMD) posted its earnings results on Tuesday, May, 12th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.01. The medical equipment provider had revenue of $8.74 million for the quarter. View Electromed's earnings history.

1 equities research analysts have issued twelve-month price targets for Electromed's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Electromed's share price to reach $12.00 in the next year. This suggests that the stock has a possible downside of 21.6%. View analysts' price targets for Electromed.

News stories about ELMD stock have been trending negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Electromed earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Electromed.

Electromed saw a increase in short interest in June. As of June 30th, there was short interest totaling 150,700 shares, an increase of 80.0% from the June 15th total of 83,700 shares. Based on an average trading volume of 190,000 shares, the short-interest ratio is presently 0.8 days. Currently, 2.3% of the company's shares are sold short. View Electromed's Current Options Chain.

Some companies that are related to Electromed include Creo Medical Group (CREO), Avacta Group (AVCT), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Titan Medical (TMD), Somnomed (SOM), Advanced Oncotherapy (AVO), Resonance Health (RHT), REVA Medical (RVA), Kromek Group (KMK), Total Brain (TTB) and EMvision Medical Devices (EMV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Electromed investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), TransEnterix (TRXC), Novavax (NVAX), AbbVie (ABBV), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Ampio Pharmaceuticals (AMPE), Energy Transfer LP Unit (ET) and Inovio Pharmaceuticals (INO).

Electromed trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ELMD."

Shares of ELMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ELMD stock can currently be purchased for approximately $15.30.

Electromed has a market capitalization of $129.81 million. Electromed employs 132 workers across the globe.

The official website for Electromed is smartvest.com.

Electromed's mailing address is 500 6th Ave NW, NEW PRAGUE, MN 56071-1134, United States. The medical equipment provider can be reached via phone at +1-952-7589299.